Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Kessler's last day

This article was originally published in The Tan Sheet

Executive Summary

Kessler's last day: Outgoing FDA commissioner participates in White House ceremony marking the beginning of FDA tobacco regulations on Feb. 28. David Kessler, MD, is going to Yale Medical School as its dean on July 1 ("The Tan Sheet" Feb. 17, In Brief). At the Feb. 28 session of the Cosmetic, Toiletry & Fragrance Association's annual meeting, President Edward Kavanaugh introduced CTFA outside counsel Peter Barton Hutt (Covington & Burling) by noting speculation that he is a candidate to succeed Kessler. "Rumors around the last week or so have you in the final three candidates," Kavanaugh said. HHS Secretary Donna Shalala reportedly has sent a long list of candidates to the White House...

You may also be interested in...



A Return Trip For Kessler At US FDA? It Wouldn’t Be The First Time It’s Happened

Two physicians experienced in agency affairs and operations, former commissioner David Kessler and former principal deputy commissioner Joshua Sharfstein, are reportedly finalists to head Biden’s FDA.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest News
UsernamePublicRestriction

Register

PS086752

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel